NICE says yes to AstraZeneca's Iressa for NSCLC and Roche's Xeloda for gastric cancer.
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, says that it is now poised to recommend AstraZeneca's Iressa (gefitinib) for some NHS non-small cell lung cancer (NSCLC) patients after initially saying that it wanted more information. The firm has also managed to convince the institute that its patient access scheme would be of benefit.